News From SABCS: EMBER-3
December 9, 2025 • ESR1 Mutated ER HER2 Advanced Breast Cancer Content Hub
In this podcast, hosts Drs. Rahul and Rohit Gosain, and Jame Abraham, MD, Cleveland Clinic, highlight findings from the EMBER-3 study comparing imlunestrant alone versus imlunestrant combined with abemaciclib in patients with hormone-receptor–positive, HER2-metastatic breast cancer. The results showed that imlunestrant monotherapy significantly improved progression-free survival (PFS) over standard endocrine therapy in patients with ESR1 mutations, while the combination therapy extended PFS for all patients, regardless of ESR1 mutation status. The combination also yielded higher response rates compared with monotherapy, offering a promising all-oral treatment option for metastatic breast cancer.
